Qol-One investigator Meeting on Rev2MDS Trial @ASH – Dec. 11 2017
By invitation only. To discus Rev2MDS (Efficacy of eltrombopag plus Lenalidomide combination therapy in patients with IPSS low and intermediate-risk myelodysplastic syndrome with isolated del5q: a multicenter, randomized, double-blind, placebo controlled study).
Collaboration Room Number 26 in Hall B1.
Leave a Reply
Want to join the discussion?Feel free to contribute!